Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) Enterprise Value (2016 - 2025)

Capricor Therapeutics has reported Enterprise Value over the past 15 years, most recently at -$318.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$318.1 million for Q4 2025, down 109.96% from a year ago — trailing twelve months through Dec 2025 was -$318.1 million (down 109.96% YoY), and the annual figure for FY2025 was -$318.1 million, down 109.96%.
  • Enterprise Value for Q4 2025 was -$318.1 million at Capricor Therapeutics, down from -$98.6 million in the prior quarter.
  • Over the last five years, Enterprise Value for CAPR hit a ceiling of -$28.5 million in Q3 2023 and a floor of -$318.1 million in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$43.5 million (2021), compared with a mean of -$74.7 million.
  • Biggest five-year swings in Enterprise Value: surged 38.81% in 2023 and later tumbled 316.81% in 2025.
  • Capricor Therapeutics' Enterprise Value stood at -$34.9 million in 2021, then fell by 18.74% to -$41.4 million in 2022, then increased by 4.67% to -$39.5 million in 2023, then crashed by 283.7% to -$151.5 million in 2024, then crashed by 109.96% to -$318.1 million in 2025.
  • The last three reported values for Enterprise Value were -$318.1 million (Q4 2025), -$98.6 million (Q3 2025), and -$122.8 million (Q2 2025) per Business Quant data.